Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of SBRT plus tislelizumab and GM-CSF in advanced non-small cell lung cancer
ChiCTR2100047048Phase 2Recruiting
- Sponsor
- Taizhou Cancer Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and sargramostim in non-small cell lung cancer (NSCLC), sponsored by Taizhou Cancer Hospital. Primary endpoint: Objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
tislelizumabsargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100047048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047048.